Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib clinical trials

A Window of Opportunity (WoO) study evaluating pembrolizumab with or without olaparib in Tertiary Lymphoid Structures (TLS)-positive selected resectable Soft Tissue Sarcoma (STS) followed by adjuvant pembrolizumab (NeoSarc)

This study is looking at new ways to treat two types of soft tissue sarcoma in adults. We're testing if adding a drug called olaparib to pembrolizumab (Keytruda) can improve treatment before surgery, and then continuing pembrolizumab afterwards. The main goal is to see how these treatments affect the cancer cells.